Primary Mitochondrial Myopathy (PMM) Archives

FDA Awards Fast Track Designation to Multiple Non-Covid-19 Candidates

Acid Disorders, Acute repetitive seizures, Coronavirus Disease (COVID-19) Pandemic, Fast Track Designation, FDA, Gene Therapy, Hypogammaglobulinemia, Imaging Agents, Infections and Myelokathexis) syndrome, Methylmalonic Acidemia (MMA), MPS Type VI, Non-Small Cell Lung Cancer (NSCLC), Phenylketonuria (PKU), Primary Mitochondrial Myopathy (PMM), Solid Tumors, WHIM (Warts

While the world has largely been focused on the development of vaccines and therapeutics for Covid-19, the U.S. Food and Drug Administration has remained busy lining up potential approvals of medications for other diseases and illnesses.

November 4, 2020/by Andrew Humphreys

Stealth Bio's neuromuscular disorder drug fails study

21st Century Cures Act, Age-Related Macular Degeneration, Barth Syndrome, Clinical Trials, Leber’s Hereditary Optic Neuropathy, Mitochondrial Disease, Mitochondrial Myopathy, Primary Mitochondrial Myopathy (PMM), Primary Mitochondrial Myopathy (PMM), Product Pipelines, R&D, Shares, Walking

Stealth BioTherapeutics Corp.’s shares crashed after the company’s lead neuromuscular disorder product candidate failed to help patients walk better and reduce fatigue.

December 20, 2019/by Reuters Health